Celsius Therapeutics is a biotechnology company that develops precision medicines for cancer and autoimmune disease patients. The company is a group of scientists, technologists, computational biologists, clinicians, and drug hunters who use single-cell genomics and machine learning analysis to find new drugs. Celsius Therapeutics was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Celsius Therapeutics is dedicated to revolutionizing the field of precision medicine by harnessing the power of single-cell genomics. Their core mission is to develop life-changing therapies for patients suffering from complex diseases, such as autoimmune disorders and cancer. By leveraging cutting-edge technology and a multidisciplinary approach, Celsius Therapeutics aims to unlock the full potential of personalized medicine, ultimately improving patient outcomes and transforming the healthcare landscape.

• Scientific rigor: Celsius Therapeutics upholds the highest standards of scientific rigor, ensuring that all research and development is conducted with integrity and accuracy.
• Collaboration: Collaboration is key to Celsius Therapeutics' success, with a focus on teamwork and open communication to drive innovation and progress.
• Patient-centricity: Celsius Therapeutics is committed to putting patients first, with a focus on developing therapies that address unmet medical needs and improve patient outcomes.
• Diversity and inclusion: Celsius Therapeutics values diversity and inclusion, recognizing that a range of perspectives and experiences leads to better science and a stronger company culture.